US Alliance Pharma: Drug Development Solutions acquisition
Bioanalytical services specialist Alliance Pharma has acquired the Drug Development Solutions contract research organization from LGC. The transaction is expected to expand the bioanalytical, analytical material testing and laboratory capabilities internationally.
“Together, Alliance and DDS will partner with customers on a global basis to provide advanced bioanalytical and analytical material services for both large and small molecules, particularly supporting many emerging bioanalytical and analytical science areas the industry needs right now,” said Dave Patteson, Alliance’s chairman of the board. “Alongside Alliance’s bioanalytical expertise, DDS adds an unrivalled breadth and depth of expertise in bioanalysis and analytical and materials science as well as two state-of-the-art analytical labs in Cambridge (Fordham), UK, and Sandwich, Kent, UK. Their Cambridge facility is one of the largest bioanalytical centers in the world with about 270 employees.”